Healthcare News Roundup: Top Global Stories, 19th-31st July, 2026

The final two weeks of July 2026 delivered one of the busiest stretches on the global health calendar in recent memory. The European Medicines Agency’s human medicines committee cleared twelve new therapies at its July 20-23 meeting, Health Canada finalized a Ministerial Reliance Order meant to speed access to treatments already vetted abroad, and the Centers for Disease Control and Prevention spent the window tracking a cyclosporiasis outbreak that surpassed 18,000 confirmed and suspected cases tied to contaminated iceberg lettuce. Each of these developments touches a different lever of the health system, yet together they describe a period when regulators, hospital executives, and biotech investors were all moving at once.

This roundup pulls together the healthcare news that mattered most between July 19 and July 31, 2026, verified against official regulatory filings, peer-reviewed journals, and company disclosures. It is built for clinicians tracking new approvals, hospital administrators watching consolidation trends, investors following biotech funding, and patients trying to make sense of what changed in their corner of the health system.

Below is a quick-reference list of the stories covered in full detail:

1. FDA clears a wave of new therapies, from an ADHD drug to a targeted lung cancer treatment
2. EMA’s CHMP recommends twelve medicines, including the first oral IL-23 receptor blocker for psoriasis
3. Health Canada approves Novartis’s RHAPSIDO and finalizes a foreign-reliance regulatory pathway
4. Australia’s PBS adds nitisinone for a rare metabolic disorder
5. NHS England confirms nationwide newborn screening for spinal muscular atrophy
6. AdventHealth and Intermountain Health sign a letter of intent to affiliate hospitals in Denver
7. Intermountain Health expands its Idaho footprint in a $795 million transaction
8. DeepHealth wins FDA clearance for an AI-powered breast ultrasound platform
9. UK biotech financing hits a five-year high as Samsung Biologics moves on PolyPeptide
10. CG Oncology publishes pivotal bladder cancer data in The Lancet Oncology
11. Amgen’s Repatha earns a CHMP nod for earlier use in cardiovascular prevention
12. CDC’s cyclosporiasis outbreak tops 18,000 cases as lettuce recall widens

FDA Clears ADHD, Oncology, and Contraceptive Therapies in a Packed Late-July Docket

The U.S. Food and Drug Administration closed out July 2026 with a run of consequential approvals that touched pediatric psychiatry, oncology, ophthalmology, and contraceptive care within the same ten-day stretch. On July 24, the agency approved Simtriyo (centanafadine) for attention-deficit hyperactivity disorder, giving clinicians a new non-stimulant option in a therapeutic category where prescribers have long sought alternatives to controlled substances. The same day, the FDA cleared Lytenava (bevacizumab-vikg), a VEGF inhibitor for neovascular age-related macular degeneration, expanding the roster of anti-VEGF therapies available to retina specialists managing an aging patient population.

Two days earlier, on July 22, the agency approved Jideytro (zidesamtinib), a ROS1-selective kinase inhibitor for previously treated ROS1-positive non-small cell lung cancer, a molecularly defined subset that represents a small but clinically distinct share of NSCLC diagnoses. Precision oncology approvals of this kind matter less for population-level impact and more for what they signal about the maturation of biomarker-driven drug development, where sponsors are increasingly comfortable running smaller, genomically enriched trials rather than broad all-comer studies. On July 29, Viatris secured approval for Gwyn Lo, a once-weekly contraceptive patch combining ethinyl estradiol and norelgestromin, adding a non-daily option to the hormonal contraception market at a moment when adherence-friendly dosing formats are drawing renewed commercial interest.

For health systems and payers, the practical question is formulary placement and prior authorization design over the coming quarter. Non-stimulant ADHD therapies typically face slower uptake than stimulants due to entrenched prescribing habits, so Simtriyo’s commercial trajectory will hinge on payer coverage decisions as much as clinical differentiation. Meanwhile, the ROS1 approval adds competitive pressure to an already crowded targeted therapy landscape in thoracic oncology, where sponsors are racing to capture a genomically narrow but high-value patient population before generic erosion reshapes the category.

Source: Drugs.com | https://www.drugs.com/newdrugs.html

EMA’s CHMP Recommends Twelve Medicines, Headlined by First Oral IL-23 Blocker for Psoriasis

The European Medicines Agency’s Committee for Medicinal Products for Human Use met July 20-23 and issued positive opinions on twelve new medicines, a meaningfully larger batch than June’s six recommendations and a sign of a regulatory pipeline that has been building through the summer. Among the standout decisions was a recommendation for the first oral therapy targeting the interleukin-23 receptor for moderate to severe plaque psoriasis, branded Icotyde, which trial data show clears skin lesions in a substantial share of patients without requiring an injectable biologic. An oral IL-23 pathway blocker, if confirmed by the European Commission, would mark a notable shift for a drug class that has so far been dominated by subcutaneous biologics.

The committee also recommended three medicines for primary hypercholesterolaemia or mixed dyslipidaemia: Lyrokaul (lerodalcibep), a monthly self-administered injection, and two oral options, Evlarco (obicetrapib combined with ezetimibe) and Ubeslo (obicetrapib alone). Separately, CHMP backed Susvimo (ranibizumab) for wet age-related macular degeneration, an ocular implant delivered surgically that reduces the frequency of intravitreal injections, following Roche’s earlier voluntary recall and relaunch of the device after manufacturing concerns. The committee additionally cleared CuraTeQ Biologics’ pegfilgrastim biosimilar Cavoley, continuing a now years-long wave of biosimilar entrants competing against Amgen’s originator Neulasta across European markets.

For European health systems managing biologic drug budgets, the psoriasis and cholesterol recommendations both point toward a broader shift: oral alternatives to injectable therapies are steadily closing the convenience gap that has long favored biologics, and payers will need to model how oral options reshape utilization once the European Commission issues its final marketing authorization decisions, typically within two to three months of a CHMP opinion. Dermatologists and cardiologists alike should expect renewed sales representative activity and formulary review requests once national reimbursement dossiers begin moving through EU member states.

Source: European Medicines Agency | https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2026

Health Canada Approves Novartis’s RHAPSIDO and Finalizes Faster Foreign-Reliance Pathway

Health Canada delivered two distinct but related pieces of news in the back half of July that together illustrate the country’s push to modernize drug review timelines. On July 27, Novartis Pharmaceuticals Canada announced that Health Canada had issued a Notice of Compliance for RHAPSIDO (remibrutinib tablets) for chronic spontaneous urticaria in adults who remain symptomatic despite antihistamine treatment, an oral BTK inhibitor supported by the phase III REMIX-1 and REMIX-2 randomized, placebo-controlled trials. Chronic spontaneous urticaria, a condition marked by recurring hives and swelling with no identifiable external trigger, has historically had few effective options beyond antihistamines and injectable biologics, making an oral targeted therapy a meaningful addition for allergists and dermatologists.

Separately, Health Canada confirmed it had approved 537 new drugs and medical devices between April and June 2026, including three generic versions of semaglutide, positioning Canada as the first G7 country to authorize generic competitors to Ozempic. Aspen Pharmacare Canada’s generic, approved July 21 in both 2 mg and 4 mg pen formats, is among those entrants. The department also published a Ministerial Reliance Order that will allow Canadian regulators to draw on decisions and scientific assessments already completed by select foreign authorities when reviewing certain drug submissions, a mechanism designed to reduce duplicative review work without lowering domestic evidentiary standards.

The generic semaglutide approvals carry direct implications for Canadian payers and patients navigating a GLP-1 market that has strained public and private drug budgets worldwide. Earlier generic entry than most peer markets could meaningfully lower per-patient costs for type 2 diabetes management, though supply chain capacity for recombinant peptide manufacturing will determine how quickly that price pressure translates into pharmacy shelf availability. The Reliance Order, meanwhile, signals a broader Canadian regulatory strategy of leaning on trusted foreign regulators, a move industry groups have welcomed as a way to keep Canada competitive as a launch market amid shifting global trade dynamics.

Source: Health Canada | https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html

Australia’s PBS Adds Nitisinone for Rare Metabolic Disorder Hereditary Tyrosinaemia Type 1

Australia’s Pharmaceutical Benefits Advisory Committee confirmed a new subsidized listing for nitisinone (Orfadin), effective July 21, 2026, for the treatment of hereditary tyrosinaemia type 1, a rare inherited metabolic disorder in which the body cannot properly break down the amino acid tyrosine. Left untreated, the condition can cause progressive liver damage, kidney dysfunction, and a heightened risk of liver cancer in affected children, making early and continuous access to nitisinone clinically critical rather than optional. The listing followed a Pharmaceutical Benefits Scheme meeting cycle that had already added ten new medicines in July, including tezepelumab for severe uncontrolled asthma, underscoring an unusually active month for subsidized medicine additions in Australia.

Hereditary tyrosinaemia type 1 affects a small number of Australian children each year, but the PBS listing matters disproportionately for those families because nitisinone therapy, taken without subsidy, carries a cost that would be prohibitive for most households over a lifetime of treatment. The Australian government’s Department of Health, Disability and Ageing framed the listing alongside the broader July PBS additions as part of a continuing effort to expand access to high-cost medicines for rare and chronic conditions.

For pediatric metabolic specialists and rare disease advocates, the listing reinforces a broader pattern in Australian drug policy: PBAC has increasingly prioritized ultra-rare pediatric metabolic conditions for subsidized listing even when patient numbers are too small to support the kind of large randomized trials regulators typically expect, relying instead on natural history data and international treatment consensus. The practical effect for clinicians managing tyrosinaemia patients is continuity of subsidized access without the administrative burden of individual patient funding applications that rare disease treatments often require in other jurisdictions.

Source: Pharmaceutical Benefits Scheme, Australian Government | https://www.pbs.gov.au/news

NHS England Confirms Nationwide Newborn Screening Rollout for Spinal Muscular Atrophy

The UK government confirmed on July 16, 2026, that newborn screening for spinal muscular atrophy will be rolled out across all of England, with the in-service evaluation launching in October 2026 across the seven laboratories already equipped to screen for the condition, covering roughly 72 percent of English newborns from the outset. The remaining six regional laboratories, serving Bristol, Cambridge, Leeds, Liverpool, Oxford, and Portsmouth, are scheduled to begin screening in October 2027, with full funding still to be secured by the Department of Health and Social Care to reach 100 percent coverage. Spinal muscular atrophy is a genetic neuromuscular disease that, without early treatment, can cause progressive and irreversible muscle weakness in infants; several approved therapies now exist that are dramatically more effective when started before symptoms appear.

The screening announcement arrived amid a broader stretch of NHS leadership and structural change in late July, including the appointment of Yvette Cooper as Secretary of State for Health and Social Care, who said improving maternity services and advancing social care reform would be immediate priorities. The reshuffle occurred as NHS England’s own functions continue to be absorbed into the Department of Health and Social Care under the Health Bill, part of the broader 10 Year Health Plan restructuring that has dominated English health policy through 2026.

For clinicians and patient advocacy groups, the SMA screening rollout represents years of campaigning translated into policy, though the phased timeline means a meaningful share of English newborns will wait until at least 2027 for full national coverage. Muscular Dystrophy UK, which has pushed for universal screening, welcomed the announcement while noting that newborn screening should not remain what its chief executive called a postcode lottery, a tension that will likely keep pressure on the Department of Health and Social Care to secure the funding needed to complete the rollout on schedule.

Source: Muscular Dystrophy UK | https://www.musculardystrophyuk.org/news/newborn-screening-announcement/

AdventHealth and Intermountain Health Sign Denver Affiliation Letter of Intent

AdventHealth and Intermountain Health signed a letter of intent on July 21, 2026, to affiliate five AdventHealth hospitals with three Intermountain hospitals in the Denver metropolitan area, adding to what has already been an unusually active year for U.S. hospital consolidation. The proposed affiliation would bring together two large nonprofit systems with overlapping Colorado footprints, a structure that typically aims to rationalize service lines, reduce duplicated capital spending, and strengthen negotiating leverage with commercial payers across a shared market. Kaufman Hall data show 40 hospital mergers and acquisitions were announced in the first half of 2026 alone, nearly matching the total volume recorded across all of 2025.

The Denver letter of intent came the same week Intermountain also disclosed a $795 million transaction increasing its stake in two Idaho hospital systems previously co-owned with private equity-backed Surgery Partners, announced July 27. Together, the two moves illustrate Intermountain’s dual consolidation strategy in 2026: deepening control in markets where it already holds a partial stake while simultaneously exploring new geographic affiliations in adjacent states. Kaufman Hall analysts have attributed the broader surge in 2026 dealmaking to hospitals becoming more strategic after a cautious 2025, when many systems paused merger conversations to assess the operating environment under federal policy shifts.

For patients and clinicians in the Denver market, affiliations of this scale typically bring years of integration work before consumers notice changes in access points, referral patterns, or service line availability. Regulators and antitrust reviewers will scrutinize the extent of geographic overlap between the two systems’ Colorado facilities, though cross-market and even in-market hospital combinations have faced comparatively less federal antitrust resistance in 2026 than in prior years, a dynamic hospital finance executives have openly acknowledged is accelerating deal volume industry-wide.

Source: Healthcare Brew | https://www.healthcare-brew.com/stories/signed-and-scrubbed-july-2026-hospital-m-and-a

DeepHealth Wins FDA Clearance for AI-Powered Breast Ultrasound Platform

DeepHealth, a RadNet subsidiary, announced on July 30, 2026, that it had received FDA 510(k) clearance for DeepHealth Breast Ultrasound, an artificial intelligence tool designed to automate lesion detection, characterization, and reporting for diagnostic breast ultrasound exams. The clearance extends DeepHealth’s existing AI-powered mammography portfolio, giving radiology departments a more complete AI-assisted breast imaging suite spanning both mammography and ultrasound modalities. The FDA has now authorized more than 1,400 AI-enabled medical devices across specialties, with radiology accounting for roughly three-quarters of that total, and breast imaging remains one of the most densely populated categories within that broader count.

Ultrasound is frequently used as a supplemental screening or diagnostic tool for women with dense breast tissue, where mammography alone can miss cancers, making standardization of image interpretation clinically significant. DeepHealth’s clearance was supported by a multi-reader multi-case study, a study design regulators commonly require to demonstrate that an AI tool improves or at minimum matches human reader performance across a range of clinical scenarios and reader experience levels, though FDA clearance under the 510(k) pathway does not by itself require prospective real-world outcome data.

For radiology practices and breast imaging centers, the clearance adds another workflow tool competing in an increasingly crowded breast AI market, and the differentiating factor for adoption will likely be integration depth with existing PACS and reporting systems rather than raw detection sensitivity, since most cleared tools in this category report comparable performance benchmarks. Payers and health system CIOs evaluating breast AI purchases will also need to weigh reimbursement uncertainty, since many AI-assisted imaging tools still lack dedicated CPT codes that guarantee incremental payment beyond the underlying imaging study.

Source: GlobeNewswire | https://www.globenewswire.com/news-release/2026/07/30/3336456/0/en/DeepHealth-Receives-FDA-Clearance-for-AI-Powered-Breast-Ultrasound.html

UK Biotech Financing Hits Five-Year High as Samsung Biologics Moves on PolyPeptide

UK biotech financing reached £2.11 billion (approximately $2.84 billion) in equity investment during the second quarter of 2026, the strongest quarterly showing in five years, according to industry data reported July 20. The figure reflects a broader European life sciences funding rebound that has coincided with a resurgent global biotech IPO market, where U.S.-listed biotech and pharma offerings have averaged 55 percent returns in 2026, sharply outperforming the broader IPO market’s negative 4.4 percent showing over the same period. At least six additional biotechs, including CRISPR-focused Scribe Therapeutics, filed for IPOs in July alone, signaling continued momentum heading into the traditionally slower August filing window.

Alongside the funding data, Samsung Biologics launched an all-cash tender offer to acquire PolyPeptide for approximately CHF 1.46 billion ($1.81 billion), a move aimed at expanding the Korean contract development and manufacturing organization’s peptide production capacity at a moment when GLP-1 and other peptide therapeutic demand continues to strain global manufacturing capacity. The deal adds to a wave of large biopharma transactions across July 2026, including Vertex Pharmaceuticals’ earlier $10 billion acquisition of Crinetics Pharmaceuticals, part of what BioSpace and other trade outlets have described as one of the most active M&A stretches the sector has seen in years, aided by a more permissive antitrust posture from U.S. regulators.

The UK funding surge carries particular significance for the country’s post-Brexit life sciences strategy, which has repeatedly sought to position London and Oxford-Cambridge biotech clusters as credible alternatives to Boston and the San Francisco Bay Area for early-stage capital formation. Whether the five-year funding high proves durable will depend heavily on whether the current wave of biotech IPO enthusiasm in the United States persists into the third quarter, since UK venture rounds and exits remain closely correlated with broader transatlantic risk appetite for clinical-stage biotech.

Source: TLDR Biotech | https://tldrbio.tech/p/biotech-pharma-updates-july-20-2026

CG Oncology Publishes Pivotal Bladder Cancer Data in The Lancet Oncology

CG Oncology announced July 27, 2026, that results from its pivotal Phase 3 BOND-003 Cohort C trial had been published in The Lancet Oncology, evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The trial reported a median duration of response of 27.9 months, a figure the study’s lead author, Mark Tyson II of the Mayo Clinic, described as among the longer durability outcomes reported in this treatment setting. Patients with this form of bladder cancer typically face a difficult choice between additional bladder-sparing therapies of uncertain durability or radical cystectomy, a life-altering surgical procedure that removes the bladder entirely.

BCG-unresponsive non-muscle invasive bladder cancer has represented a persistent unmet need in urologic oncology, particularly as global BCG supply shortages have periodically limited access to the decades-old standard first-line immunotherapy. Cretostimogene grenadenorepvec is an oncolytic viral immunotherapy, a treatment class that works by selectively replicating within and destroying cancer cells while stimulating a broader antitumor immune response, distinguishing it mechanistically from the checkpoint inhibitors and antibody-drug conjugates that have dominated recent oncology approvals.

The peer-reviewed publication in a journal of The Lancet Oncology’s standing adds substantial credibility to data CG Oncology has previously presented at conference settings, and it positions the company for a regulatory submission that urologists and bladder-sparing treatment advocates will be watching closely. If the therapy ultimately reaches approval, it would offer a meaningful bladder-preservation alternative for a patient population that has had limited options beyond cystectomy once BCG therapy fails, though real-world durability and retreatment patterns will need to be tracked as the therapy moves toward broader clinical use.

Source: GlobeNewswire | https://www.globenewswire.com/news-release/2026/07/27/3333936/0/en/CG-Oncology-Announces-Publication-of-Pivotal-Phase-3-BOND-003-Cohort-C-Study-Results-in-The-Lancet-Oncology.html

Amgen’s Repatha Earns CHMP Backing for Earlier Cardiovascular Risk Reduction

Amgen announced July 29, 2026, that the CHMP had adopted a positive opinion supporting broader use of Repatha (evolocumab) for adults with established or high risk for atherosclerotic cardiovascular disease, extending the PCSK9 inhibitor’s potential use to earlier prevention before a first heart attack or stroke rather than solely as secondary prevention after a cardiovascular event has already occurred. The recommendation was based on the Phase 3 VESALIUS-CV trial, which enrolled more than 12,000 patients, one of the largest cardiovascular outcomes trials conducted for a lipid-lowering therapy in recent years.

Repatha has been commercially available for secondary prevention in patients with established cardiovascular disease for nearly a decade, but expanding its label to earlier, primary-prevention-adjacent use in high-risk patients would meaningfully widen its addressable population across European health systems. PCSK9 inhibitors have historically faced reimbursement friction in many European markets due to their cost relative to generic statins, and payers will need to weigh the VESALIUS-CV outcomes data against budget impact models as national health technology assessment bodies evaluate the expanded indication once the European Commission finalizes its decision.

For cardiologists managing patients with elevated LDL cholesterol and multiple risk factors but no prior cardiovascular event, an earlier-use indication could shift prescribing patterns meaningfully, particularly for patients who have not achieved adequate LDL control on statins alone or who cannot tolerate statin therapy. The scale of the VESALIUS-CV trial population also gives the cardiology community one of the more robust evidence bases available for evaluating PCSK9 inhibition earlier in the atherosclerotic disease continuum, a question that has been debated in guideline committees for years.

Source: PR Newswire | https://www.prnewswire.com/news-releases/positive-chmp-opinion-supports-broader-use-of-amgens-repatha-before-a-first-heart-attack-or-stroke-302837810.html

CDC’s Cyclosporiasis Outbreak Tops 18,000 Cases as Lettuce Recall Widens

The CDC reported July 28, 2026, that confirmed and suspected cyclosporiasis cases from the current U.S. outbreak had reached 18,207, with the agency actively investigating multiple case clusters, including a nine-state outbreak linked to iceberg lettuce. Taylor Farms recalled iceberg lettuce sourced from central Mexico on July 17 after an FDA notice, with the affected product distributed to 27 states through both retail grocery channels and food service supply chains, a distribution footprint wide enough to complicate the traceback investigation that CDC and FDA officials have been conducting jointly with state health departments. The 2026 cyclosporiasis season, which the CDC defines as running from May 1 through August 31, began generating case counts substantially above the same period in 2025, prompting the agency to shift to weekly rather than periodic surveillance updates.

Cyclosporiasis is a gastrointestinal illness caused by the parasite Cyclospora cayetanensis, transmitted through contaminated food or water rather than person-to-person contact, which distinguishes outbreak response protocols from those used for more transmissible pathogens. Case demographics reported by CDC show a median patient age of 44, with illness onset dates ranging from May 1 through late July, reflecting both the initial cluster and subsequent waves tied to the widening lettuce recall. Public health officials have cautioned that the true case count is almost certainly higher than reported figures, since many people recover without seeking medical care and are never tested for the parasite.

For hospital emergency departments and primary care clinics, particularly in the nine states directly implicated in the lettuce-linked cluster, the outbreak underscores the continued vulnerability of fresh produce supply chains to contamination events that can scale rapidly once implicated products reach national food service distribution. Infection control professionals have emphasized that while person-to-person transmission is rare, standard precautions remain appropriate for hospitalized patients presenting with acute diarrhea, and clinicians in affected states have been urged to maintain a lower threshold for cyclosporiasis testing given the scale of the ongoing multistate investigation.

Source: American Hospital Association News | https://www.aha.org/news/headline/2026-07-29-cdc-reports-more-18000-confirmed-or-suspected-cyclosporiasis-cases

Key Regulatory and Deal Activity, July 19-31, 2026

Closing Section

Late July 2026 made clear that no single region or category is driving global healthcare news on its own; regulatory momentum in Brussels, hospital consolidation in the American West, and a widening foodborne outbreak all demanded attention in the same ten-day window.

Clinicians, investors, and health system leaders alike will want to keep an eye on how the EMA’s psoriasis and cholesterol recommendations translate into national reimbursement decisions, and whether the CDC’s cyclosporiasis case count continues climbing before the outbreak season closes at the end of August. Stay tuned for the next roundup covering the first weeks of August 2026.